392 related articles for article (PubMed ID: 8498129)
1. Immunocytochemical detection of ovarian carcinoma cells in serous effusions.
Cuijpers VM; Boerman OC; Salet van de Pol MR; Vooijs GP; Poels LG; Ramaekers FC
Acta Cytol; 1993; 37(3):272-9. PubMed ID: 8498129
[TBL] [Abstract][Full Text] [Related]
2. Monoclonal antibody against human ovarian tumor-associated antigens.
Poels LG; Peters D; van Megen Y; Vooijs GP; Verheyen RN; Willemen A; van Niekerk CC; Jap PH; Mungyer G; Kenemans P
J Natl Cancer Inst; 1986 May; 76(5):781-91. PubMed ID: 3517452
[TBL] [Abstract][Full Text] [Related]
3. Patterns of reactivity of four novel monoclonal antibodies (B72.3, DF3, B1.1 and B6.2) with cells in human malignant and benign effusions.
Szpak CA; Johnston WW; Lottich SC; Kufe D; Thor A; Schlom J
Acta Cytol; 1984; 28(4):356-67. PubMed ID: 6205527
[TBL] [Abstract][Full Text] [Related]
4. Carbohydrate antigen expression in primary tumors, metastatic lesions, and serous effusions from patients diagnosed with epithelial ovarian carcinoma: evidence of up-regulated Tn and Sialyl Tn antigen expression in effusions.
Davidson B; Berner A; Nesland JM; Risberg B; Kristensen GB; Tropé CG; Bryne M
Hum Pathol; 2000 Sep; 31(9):1081-7. PubMed ID: 11014575
[TBL] [Abstract][Full Text] [Related]
5. [GC12, marker of cells of mesodermal origin. Value and application to cytodiagnosis of serous effusions].
Daste G; Gioanni J; Lauque D; Kremps M; Mazeau C; Paquis P; Schneider M
Arch Anat Cytol Pathol; 1997; 45(4):185-91. PubMed ID: 9406475
[TBL] [Abstract][Full Text] [Related]
6. Immunocytochemical staining of smears and corresponding cell blocks from serous effusions: a follow-up and comparative investigation.
Jensen ML; Johansen P
Diagn Cytopathol; 1996 Jul; 15(1):33-6. PubMed ID: 8807249
[TBL] [Abstract][Full Text] [Related]
7. Distinction between carcinoma cells and mesothelial cells in serous effusions. Usefulness of immunohistochemistry.
Tickman RJ; Cohen C; Varma VA; Fekete PS; DeRose PB
Acta Cytol; 1990; 34(4):491-6. PubMed ID: 2197840
[TBL] [Abstract][Full Text] [Related]
8. A new epithelial membrane antigen (Calam 27) as a marker of carcinoma in serous effusions.
Gioanni J; Caldani C; Zanghellini E; Mazeau C; Duplay H; Ferrua B; Schneider M
Acta Cytol; 1991; 35(3):315-9. PubMed ID: 2042433
[TBL] [Abstract][Full Text] [Related]
9. Carcinoma of ovarian and other origins in effusions. Immunocytochemical study with a panel of monoclonal antibodies.
Flynn MK; Johnston W; Bigner S
Acta Cytol; 1993; 37(4):439-47. PubMed ID: 8328236
[TBL] [Abstract][Full Text] [Related]
10. Immunocytochemistry of malignant mesothelioma: OV632 as a marker of malignant mesothelioma.
Delahaye M; Hoogsteden HC; Van der Kwast TH
J Pathol; 1991 Oct; 165(2):137-43. PubMed ID: 1744800
[TBL] [Abstract][Full Text] [Related]
11. Marker profile of different phases in the transition of normal human ovarian epithelium to ovarian carcinomas.
van Niekerk CC; Boerman OC; Ramaekers FC; Poels LG
Am J Pathol; 1991 Feb; 138(2):455-63. PubMed ID: 1992770
[TBL] [Abstract][Full Text] [Related]
12. Density distribution and immunological reactivity of tumor cells from peritoneal effusions of patients with ovarian neoplasms.
Harłozińska A; Bar JK; Cisło M; Richter R; Rabczyński J
Anal Cell Pathol; 1992 Jan; 4(1):1-12. PubMed ID: 1370907
[TBL] [Abstract][Full Text] [Related]
13. D2-40 is not a specific marker for cells of mesothelial origin in serous effusions.
Bassarova AV; Nesland JM; Davidson B
Am J Surg Pathol; 2006 Jul; 30(7):878-82. PubMed ID: 16819331
[TBL] [Abstract][Full Text] [Related]
14. Changes in expression of differentiation markers between normal ovarian cells and derived tumors.
Van Niekerk CC; Ramaekers FC; Hanselaar AG; Aldeweireldt J; Poels LG
Am J Pathol; 1993 Jan; 142(1):157-77. PubMed ID: 7678716
[TBL] [Abstract][Full Text] [Related]
15. CA 125 in ovarian cysts, serous effusions and peritoneal washings: immunocytochemical expression.
Carico E; Chicchirichi R; Atlante M; Giovagnoli M; Vecchione A
Anticancer Res; 1995; 15(2):631-4. PubMed ID: 7763049
[TBL] [Abstract][Full Text] [Related]
16. WT1, monoclonal CEA, TTF1, and CA125 antibodies in the differential diagnosis of lung, breast, and ovarian adenocarcinomas in serous effusions.
Zhu W; Michael CW
Diagn Cytopathol; 2007 Jun; 35(6):370-5. PubMed ID: 17497661
[TBL] [Abstract][Full Text] [Related]
17. Distribution of OV-TL 3 and MOv18 in normal and malignant ovarian tissue.
Buist MR; Molthoff CF; Kenemans P; Meijer CJ
J Clin Pathol; 1995 Jul; 48(7):631-6. PubMed ID: 7560169
[TBL] [Abstract][Full Text] [Related]
18. Comparative immunohistochemical study of four monoclonal antibodies directed against ovarian carcinoma-associated antigens.
Boerman OC; van Niekerk CC; Makkink K; Hanselaar TG; Kenemans P; Poels LG
Int J Gynecol Pathol; 1991; 10(1):15-25. PubMed ID: 2007534
[TBL] [Abstract][Full Text] [Related]
19. Monoclonal antibodies against ovarian carcinoma-associated antigens, raised by immunization with cyst fluids.
Boerman O; Makkink K; Massuger L; Thomas C; Kenemans P; Hanselaar T; Poels L
Anticancer Res; 1989; 9(3):551-8. PubMed ID: 2764501
[TBL] [Abstract][Full Text] [Related]
20. Malignant ascites of serous papillary ovarian adenocarcinoma. An immunocytochemical study of the tumor cells.
Guzman J; Hilgarth M; Bross KJ; Ross A; Wiehle U; Kresin V; Grunert F; von Kleist S
Acta Cytol; 1988; 32(4):519-22. PubMed ID: 3041721
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
